• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Impact of pre ‐existing or new‐onset atrial fibrillation on 30‐day clinical outcomes following Transcatheter Aortic Valve Replacement: Results From The BRAVO 3 Randomized Trial
Conclusions: Prior or new‐onset AF within 30 days of transfemoral TAVR is noted in more than one‐third of patients. Despite greater baseline comorbidities than non‐AF patients, AF was not associated with greater risk of adjusted 30‐day outcomes. In the BRAVO 3 trial, early outcomes were similar regardless of anticoagulant strategy in each group. This article is protected by copyright. All rights reserved.
Source: Catheterization and Cardiovascular Interventions - May 1, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Christian Hengstenberg, Jaya Chandrasekhar, Samantha Sartori, Thierry Lefevre, Ghada Mikhail, Nicolas Meneveau, Christophe Tron, Raban Jeger, Christian Kupatt, Birgit Vogel, Serdar Farhan, Sabato Sorrentino, Madhav Sharma, Clayton Snyder, Oliver Husser, P Tags: VSD ‐ Valvular and Structural Heart Diseases Source Type: research

Femoral vascular closure device use, bivalirudin anticoagulation and bleeding after primary angioplasty for STEMI: Results from the HORIZONS‐AMI trial
Conclusion: In patients undergoing transfemoral primary PCI for STEMI, VCD use was associated with significantly lower non‐CABG major bleeding irrespective of anticoagulation strategy. © 2014 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - September 1, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Timothy A. Sanborn, Matthew I. Tomey, Roxana Mehran, Philippe Généreux, Bernhard Witzenbichler, Sorin J. Brener, Ajay J. Kirtane, Thomas C. McAndrew, Ran Kornowski, Dariusz Dudek, Eugenia Nikolsky, Gregg W. Stone Tags: Original Studie Source Type: research

Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: Results from the HORIZONS‐AMI trial
ConclusionIn patients undergoing transfemoral primary PCI for STEMI, VCD use was associated with significantly lower non‐CABG major bleeding irrespective of anticoagulation strategy. © 2014 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - October 28, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Timothy A. Sanborn, Matthew I. Tomey, Roxana Mehran, Philippe Généreux, Bernhard Witzenbichler, Sorin J. Brener, Ajay J. Kirtane, Thomas C. McAndrew, Ran Kornowski, Dariusz Dudek, Eugenia Nikolsky, Gregg W. Stone Tags: Coronary Artery Disease Source Type: research